CVRx announces news on outpatient payment for Barostim

CVRx (CVRX) announced that the Centers for Medicare and Medicaid Services, CMS, has proposed to keep the Barostim implant procedure as part of the New Technology Ambulatory Payment Classification, APS, 1580, with an associated payment of approximately $45,000 for procedures performed in the outpatient setting. CMS is also soliciting comments about the need for a Level 6 Neurostimulator APC. The company expects CMS will publish the 2026 Medicare Hospital Outpatient Prospective Payment System final rule in November, which is expected to take effect on January 1, 2026.